Shots:

• The P-III trial involves assessing of DRL_RI vs Roche’s MabThera (rituximab) in 284 patients including 26 Koreans- with stage II-IV- CD20 positive- and follicular lymphoma previously treated have low tumor burden- evaluating its efficacy- safety- and immunogenicity
• Dr. Reddy’s plan to evaluate DRL_RI in Korea while Paraxel to provide clinical research services and Korea’s MFDS has also approved P-III trial for DRL_RI on Wednesday
• DRL_RI is a mAb and a biosimilar of Roche’s MabThera and will be targeted for lymphoma- chronic lymphocytic leukemia- rheumatoid arthritis- granulomatosis with polyangiitis and microscopic polyangiitis

Click here to­ read full press release/ article | Ref: KoreaBioMed | Image: Twitter